Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia

Blood

Volumn 100, Issue 9, 2002, Pages 3344-3351

  Molica, Stefano ^a   Vacca, Angelo ^a   Ribatti, Domenico ^b   Cuneo, Antonio ^b   Cavazzini, Francesco ^c   Levato, Domenico ^c   Vitelli, Gaetano ^d   Tucci, Luigi ^d   Roccaro, Aldo M ^a   Dammacco, Franco ^a  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FIBROBLAST GROWTH FACTOR 2; IRON; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; B CELL LEUKEMIA; BONE MARROW BIOPSY; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IRON DEFICIENCY ANEMIA; KARYOTYPE; MALE; MICROVASCULATURE; PERNICIOUS ANEMIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; TUMOR GROWTH; TUMOR VOLUME;

EID: 0036838537     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0084     Document Type: Article

References (43)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
2. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow. J Pathol. 1998;184:119-122.
3. Tung-Ping Poon R, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207-1225.
4. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haemat. 1994;87:503-508.
5. Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer. 1999;79:965-970.
6. Vacca A, Moretti S, Ribatti D, et al. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinase-2 and -9. Eur J Cancer. 1997;33:1685-1692.
7. Padrò T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-2644.
8. Lundberg LG, Lerner L, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol. 2000;157:15-19.
9. Thomas DA. Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders. Semin Hematol. 2000;37:S26-S34.
10. Molica S. Angiogenesis in B-cell chronic lymphocytic leukemia: Methods of study, clinical significance and prognostic implications. Leuk Lymphoma. 2001;42:603-607.
11. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
12. Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;107:605-610.
13. Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96:768-770.
14. Chen H, Treeweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000;96:3181-3187.
15. Menzel T, Rahaman Z, Calleja E, et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabina. Blood. 1996;87:1056-1063.
16. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia. 2000;14:1414-1418.
17. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-212.
18. Cheson BD, Bennett JM, Grever M, et al. National Institute-sponsored working guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
19. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy NR, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
20. Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. Bone marrow histologic pattern: the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 1984;64:642-653.
21. Montserrat E, Vinolas N, Reverter JC, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br J Haematol. 1986;62:567-578.
22. Elias H, Hyde DM. Stereological measurements of isotropics structures, In: Elias H, Hyde DM, eds. A Guide to Practical Stereology. Basel: Karger; 1983:25-44.
23. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.
24. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd Ed, Oxford, England: Blackwell Scientific; 1987.
25. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of disease. Blood. 2002;99:1023-1029.
26. Vacca A, Frigeri A, Ribatti D, et al. Microvessel over-expression of acquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. Br J Haematol. 2001;113:415-421.
27. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance of VEGF measurements and cancer biology. Br J Cancer. 1998;77:956-964.
28. Cuneo A, Bigoni R, Rigolin GM, et al. Acquired deletion of the ataxia teleangiectasia (ATM) locus in non-Hodgkin's lymphoma: Correlation with clinicobiological features. J Clin Oncol. 2000;18:2607-2614.
29. Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood. 1991;78:895-899.
30. Molica S. Prognostic factors in chronic lymphocytic leukemia. In: Cheson BD, ed. Chronic Lymphoid Leukemias. 2nd ed. New York, NY: Marcel Dekker; 2001:231-260.
31. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single institution study of 200 patients. Blood. 2000;96:3712-3718.
32. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
33. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6:3111-3116.
34. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med. 1998;338:1506-1514.
35. Richardson P, Hideshima T, Anderson K. Thalidomide: Emerging role in cancer medicine. Annu Rev Med. 2002;53:629-657.
36. Cooke SP, Boxer GM, Lawrence L, et al. Strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex. Cancer Res. 2001;61:3653-3659.
37. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 2000;19:173-179.
38. Hamada J, Cavanaugh PG, Lotan O. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer. 1992;66:349-354.
39. Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco F. The role of mast cells in tumour angiogenesis. Br J Haematol. 2001;115:514-521.
40. Guidi A, Abu-Jawdeh GM, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression in cervical neoplasia. J Nat Cancer Inst. 1995;87:1237-1245.
41. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasm. Lab Invest. 1996;74:1105-1115.
42. Chow NH, Hsu PI, Lin XZ, et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study. Hum Pathol. 1997;28:698-795.
43. Sezer O, Niemoller K, Kaufmann O, et al. Decrease in bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haemat. 2001;66:238-244.